100 related articles for article (PubMed ID: 25099655)
1. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Whitworth P; Stork-Sloots L; de Snoo FA; Richards P; Rotkis M; Beatty J; Mislowsky A; Pellicane JV; Nguyen B; Lee L; Nash C; Gittleman M; Akbari S; Beitsch PD
Ann Surg Oncol; 2014 Oct; 21(10):3261-7. PubMed ID: 25099655
[TBL] [Abstract][Full Text] [Related]
2. Pathological responses and long-term outcome analysis after neoadjuvant chemotheraphy in breast cancer patients from Kuwait over a period of 15 years.
Krishnan Y; Alawadhi SA; P S S; Gopal M; Thuruthel S
Ann Saudi Med; 2013; 33(5):443-50. PubMed ID: 24188937
[TBL] [Abstract][Full Text] [Related]
3. Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR.
Caselli E; Pelliccia C; Teti V; Bellezza G; Mandarano M; Ferri I; Hartmann K; Laible M; Sahin U; Varga Z; Lupi C; Stracci F; Sidoni A
PLoS One; 2021; 16(9):e0255580. PubMed ID: 34555047
[TBL] [Abstract][Full Text] [Related]
4. Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer.
Yi X; Hu S; Ma M; Huang D; Zhang Y
Clin Transl Oncol; 2024 Apr; 26(4):880-890. PubMed ID: 37702827
[TBL] [Abstract][Full Text] [Related]
5. Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy.
Chaudhary LN; Jorns JM; Sun Y; Cheng YC; Kamaraju S; Burfeind J; Gonyo MB; Kong AL; Patten C; Yen T; Cortina CS; Carson E; Johnson N; Bergom C; Tsaih SW; Banerjee A; Wang Y; Chervoneva I; Weil E; Chitambar CR; Rui H
Breast Cancer Res Treat; 2023 Oct; 201(3):387-396. PubMed ID: 37460683
[TBL] [Abstract][Full Text] [Related]
6. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LFA; Schmidt MK; van Beers EH; Cornelissen S; Holtkamp M; Froklage FE; de Vries EGE; Schrama JG; Wesseling J; van de Vijver MJ; van Tinteren H; de Bruin M; Hauptmann M; Rodenhuis S; Linn SC
Ann Oncol; 2011 Jul; 22(7):1561-1570. PubMed ID: 21135055
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Pusztai L; Yau C; Wolf DM; Han HS; Du L; Wallace AM; String-Reasor E; Boughey JC; Chien AJ; Elias AD; Beckwith H; Nanda R; Albain KS; Clark AS; Kemmer K; Kalinsky K; Isaacs C; Thomas A; Shatsky R; Helsten TL; Forero-Torres A; Liu MC; Brown-Swigart L; Petricoin EF; Wulfkuhle JD; Asare SM; Wilson A; Singhrao R; Sit L; Hirst GL; Berry S; Sanil A; Asare AL; Matthews JB; Perlmutter J; Melisko M; Rugo HS; Schwab RB; Symmans WF; Yee D; Van't Veer LJ; Hylton NM; DeMichele AM; Berry DA; Esserman LJ
Cancer Cell; 2021 Jul; 39(7):989-998.e5. PubMed ID: 34143979
[TBL] [Abstract][Full Text] [Related]
8. Intertumoral heterogeneity of bifocal breast cancer: a morphological and molecular study.
Finsterbusch K; van Diest PJ; Focke CM
Breast Cancer Res Treat; 2024 Jun; 205(2):413-421. PubMed ID: 38453779
[TBL] [Abstract][Full Text] [Related]
9. Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer.
Ryu HH; Ahn SH; Kim SO; Kim JE; Kim JS; Ahn JH; Jung KH; Kim SB; Ko BS; Lee JW; Son BH; Shin HJ; Kim HH; Gong GY; Kim HJ
Sci Rep; 2021 May; 11(1):10510. PubMed ID: 34006898
[TBL] [Abstract][Full Text] [Related]
10. Predictive markers for pathological complete response (pCR) after neo-adjuvant chemotherapy in HER2-positive breast carcinoma.
Van Bockstal MR; Dano H; Benhaddi N; Dubois D; Vanderveken J; Van Marcke C; Vandermeulen A; Duhoux FP; Vernaeve H; Berlière M; Galant C
Histol Histopathol; 2024 Feb; 39(2):153-164. PubMed ID: 37204204
[TBL] [Abstract][Full Text] [Related]
11. RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.
Link T; Blohmer JU; Schmitt WD; Kuhlmann JD; Just M; Untch M; Stotzer O; Fasching PA; Thill M; Reinisch M; Schneeweiss A; Wimberger P; Seiler S; Huober J; Jackisch C; Rhiem K; Hanusch C; Sinn BV; Nekljudova V; Loibl S; Denkert C
Clin Cancer Res; 2023 Nov; 29(22):4606-4612. PubMed ID: 37725572
[TBL] [Abstract][Full Text] [Related]
12. Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study.
Berg T; Jensen MB; Celik A; Talman ML; Misiakou MA; Knoop AS; Nielsen FC; Ejlertsen B; Rossing M
JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38587073
[TBL] [Abstract][Full Text] [Related]
13. HER2GAN: Overcome the Scarcity of HER2 Breast Cancer Dataset Based on Transfer Learning and GAN Model.
Mirimoghaddam MM; Majidpour J; Pashaei F; Arabalibeik H; Samizadeh E; Roshan NM; Rashid TA
Clin Breast Cancer; 2024 Jan; 24(1):53-64. PubMed ID: 37926662
[TBL] [Abstract][Full Text] [Related]
14. Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test.
Mittempergher L; Delahaye LJ; Witteveen AT; Snel MH; Mee S; Chan BY; Dreezen C; Besseling N; Luiten EJ;
Transl Oncol; 2020 Apr; 13(4):100756. PubMed ID: 32208353
[TBL] [Abstract][Full Text] [Related]
15. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Whitworth P; Beitsch P; Mislowsky A; Pellicane JV; Nash C; Murray M; Lee LA; Dul CL; Rotkis M; Baron P; Stork-Sloots L; de Snoo FA; Beatty J
Ann Surg Oncol; 2017 Mar; 24(3):669-675. PubMed ID: 27770345
[TBL] [Abstract][Full Text] [Related]
16. MammaPrint Reduces Breast Cancer Overtreatment.
Cancer Discov; 2016 Jun; 6(6):OF4. PubMed ID: 27095361
[TBL] [Abstract][Full Text] [Related]
17. [uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].
Bellocq JP; Luporsi E; Barrière J; Bonastre J; Chetritt J; Le Corroller AG; de Crémoux P; Fina F; Gauchez AS; Kassab-Chahmi D; Lamy PJ; Martin PM; Mazouni C; Peyrat JP; Romieu G; Verdoni L; Mazeau-Woynar V
Ann Pathol; 2014 Oct; 34(5):349-51. PubMed ID: 25439987
[TBL] [Abstract][Full Text] [Related]
18. Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.
Bayraktar S; Royce M; Stork-Sloots L; de Snoo F; Glück S
Med Oncol; 2014 Oct; 31(10):163. PubMed ID: 25186065
[TBL] [Abstract][Full Text] [Related]
19. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
Seguí MÁ; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna SM; Gracia A
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):889-99. PubMed ID: 25213317
[TBL] [Abstract][Full Text] [Related]
20. [uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].
Luporsi E; Bellocq JP; Barrière J; Bonastre J; Chetritt J; Le Corroller AG; de Cremoux P; Fina F; Gauchez AS; Lamy PJ; Martin PM; Mazouni C; Peyrat JP; Romieu G; Verdoni L; Mazeau-Woynar V; Kassab-Chahmi D;
Bull Cancer; 2015 Sep; 102(9):719-29. PubMed ID: 26235416
[No Abstract] [Full Text] [Related]
[Next] [New Search]
